Imaging Diagnostic Systems, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Private equity financing provides $25 mil. funding commitment from an institutional investor. The developer of the CTLM laser-based breast imaging device, designed to aid in the diagnosis of breast abnormalities without using breast compression or x-rays, plans to use the proceeds from the financing "for the ongoing clinical programs, product development, working capital and general corporate purposes," the firm states. The device utilizes laser technology and computed algorithms that create "contiguous cross-sectional slice images of the breast." Data from ongoing clinical trials at two sites are to be submitted to FDA in "late summer or early this fall," IDS says. The funding commitment provides the flexibility to draw upon the capital when needed, the firm notes
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.